Shots: The EMA’s CHMP has issued a positive opinion recommending the marketing authorization for regdanvimab (CT-P59) in adults with COVID-19 who do not require supplemental oxygen & are at increased […]readmore
Tags : CT-P59
Clinical Trials
COVID-19
Celltrion Reports Results of Regdanvimab (CT-P59) in Pre-Clinical Study Against
Shots: The preclinical results have demonstrated that CT-P59 has neutralizing effect against the South African variant and showed a reduction in viral load of SARS-CoV-2 and in binding affinity against […]readmore
Shots: The P-II/III study involves assessing of CT-P59 (40mg/kg, 80mg/kg) vs PBO in 327 patients with mild-to-mod. symptoms of COVID-19 Results: reduction in progression rates (54% for mild-to-mod. patients & […]readmore
Shots: The P-I clinical trial involves assessing CT-P59 (20/40/80 mg/kg) vs PBO in 18 patients with mild symptoms of SARS-COV-2 infection who were randomized into 3 cohorts Results: patients demonstrated […]readmore
Shots: The initiation of the post-exposure prophylaxis clinical trial follows Korean MFDS’ IND approval on Oct 08, 2020 The study will assess the preventive effect & safety of CT-P59 in […]readmore
Shots: The Korean MFDS has approved Celltrion’s IND to initiate a P-I trial of CT-P59 in patients with COVID-19. The company has initiated the enrollment and is set to evaluate […]readmore